Search This Blog

Thursday, July 1, 2021

Arcutis ends trial of vitiligo treatment candidate, to reformulate

 

  • Formulation-related observations from ARQ-252 trial in chronic hand eczema informed early termination of Phase 2a ARQ-252 trial in vitiligo

  • Company progressing new formulation with goal of greater drug delivery to targets in the skin

Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)